BofA Raises Eli Lilly Price Target on GLP-1 Growth

Bank of America (BofA) has raised its price target for Eli Lilly, citing strong growth potential in the company's GLP-1 drugs. Analysts noted that increasing sales of these drugs, particularly for diabetes and obesity treatment, are expected to significantly contribute to Eli Lilly's revenue. The revised target price indicates a higher level compared to Eli Lilly's current market value, creating a positive sentiment among investors regarding the company's growth prospects. Despite competition in the GLP-1 market, Eli Lilly's robust product portfolio and R&D investments support the bank's optimistic outlook. Eli Lilly's shares saw a slight uptick following the news. However, market-wide demand for GLP-1 drugs and the company's leading position in this field are considered critical factors for long-term growth. BofA's report reinforced confidence in the company's financial performance. This is not investment advice.

📊 LLY — Piyasa Yorumu

▲ up · 65%

The news reflects a positive institutional view on Eli Lilly's growth potential in GLP-1 drugs, which could provide short-term support for the stock. Technical indicators also point to a strong uptrend: although the RSI at 71 is approaching overbought territory, the MACD remains above its signal line and positive. The price is trading well above the 20- and 50-day moving averages, with a notable 4.9% increase in the last 24 hours. However, the elevated RSI level may pose some risk of profit-taking or consolidation in the near term. Therefore, while the upward trend continues, a cautiously optimistic approach is warranted.

RSI 14

71.3

MACD

15.54

24h Δ

4.92%

Canlı Grafikler